Novartis invests $170 million for ex-U.S. rights to Luxturna

Swiss-based Novartis Pharmaceuticals has acquired rights to commercialize Luxturna—Spark Therapeutics’ gene therapy for inherited retinal dystrophy—outside of the United States.

https://www.aao.org/headline/novartis-invests-170-million-ex-u-s-rights-to-luxt

Comments

Popular posts from this blog

I Spy a Stye in Your Eye

Post-LASIK Refraction and Pregnancy – Much Ado About Nothing?